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Abstract
Background: Presentation of peptides on Major Histocompatibility Complex (MHC) molecules is the cornerstone in immune
system activation and increased knowledge of the characteristics of MHC ligands and their source proteins is highly
desirable.
Methodology/Principal Finding: In the present large-scale study, we used a large data set of proteins containing
experimentally identified MHC class I or II ligands and examined the proteins according to their expression profiles at the
mRNA level and their Gene Ontology (GO) classification within the cellular component ontology. Proteins encoded by highly
abundant mRNA were found to be much more likely to be the source of MHC ligands. Of the 2.5% most abundant mRNAs as
much as 41% of the proteins encoded by these mRNAs contained MHC class I ligands. For proteins containing MHC class II
ligands, the corresponding percentage was 11%. Furthermore, we found that most proteins containing MHC class I ligands
were localised to the intracellular parts of the cell including the cytoplasm and nucleus. MHC class II ligand donors were, on
the other hand, mostly membrane proteins.
Conclusions/Significance: The results contribute to the ongoing debate concerning the nature of MHC ligand-containing
proteins and can be used to extend the existing methods for MHC ligand predictions by including the source protein’s
localisation and expression profile. Improving the current methods is important in the growing quest for epitopes that can
be used for vaccine or diagnostic purposes, especially when it comes to large DNA viruses and cancer.
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Introduction
CD8+ T lymphocytes are activated on recognition of MHC
class I molecules in complex with peptide ligands, whereas CD4+
T lymphocytes are activated by MHC class II molecules in
complex with peptide ligands. In both cases, the result is an
immune response directed against, e.g., infected or neoplastic cells.
Many methods have been developed for predicting which peptides
are presented by MHC class I and II molecules [1–4], since these
peptides could be used for vaccine or diagnostic purposes. The
focus of the available methods is, however, to identify the optimal
peptides from provided protein sequences, while little effort has
been made towards developing schemes for prioritisation of the
optimal protein candidates from a pool of proteins. To this end,
increased knowledge about the general characteristics of proteins
containing MHC ligands is desirable. In this study, we have
focused on protein cellular localisation and expression profile.
The main function of MHC class I molecules is thought to be
presentation of endogenous foreign peptide antigens. The pathway
leading to MHC class I presentation begins when proteins are
degraded by the proteasome, which is present in the cytosol.
Accordingly, it is a widespread view that MHC class I ligands are
predominantly recruited from cytosolic proteins, while transmem-
brane proteins only rarely donate MHC class I ligands [5–7]. In a
study from 2004, the source of B*1801-restricted MHC class I
ligands was examined. Here it was found that these peptides are
derived from proteins of almost all compartments in the cell,
although a small over-representation of proteins from the
cytoplasmic compartment was found [8]. In an alternative view,
Yewdell and Nicchitta suggest that cell-surface proteins and even
secreted proteins are equally efficient and probable sources of
MHC class I antigenic peptides as cytosolic or nuclear proteins [9].
In contrast to MHC class I molecules, MHC class II molecules
are thought to function mainly in the presentation of exogenous
foreign peptide antigens. Nevertheless, small-scale studies have
shown that a large fraction of the presented MHC class II ligands
are derived from host cell membrane-bound proteins or host
proteins resident in endosomes or lysosomes [7,10,11].
Yewdell has proposed that the peptides presented by MHC
molecules primarily originate from defective ribosomal products
(DRiPs), which are defective forms of gene products that are
degraded more rapidly than the standard, functional form [12].
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7448
DRiPs would enable MHC class I molecules to monitor protein
synthesis rates rather than protein concentrations, and offer the
possibility of rapid detection of virus-infected cells. One implication
of the DRiP hypothesis is that the correlation between protein
concentration and the probability that the protein donates anMHC
class I ligand is expected to be weak. In line with this, it has been
observed that only a limited correlation exists between the amounts
of MHC class I ligands presented by the cells and the relative
amounts of source proteins from which these ligands are derived
[13]. Other studies have examined the correlation between mRNA
levels and the cells surface density of MHC class I ligands
originating from the proteins encoded by the mRNA. In one study,
mRNA levels were determined using DNAmicroarrays, while levels
of MHC class I molecules with peptide cargo were determined by
mass spectrometry in both human renal cell carcinoma and
autologous normal tissue [14]. In comparing mRNA levels and
corresponding MHC class I ligand presentation ratios between
normal versus cancer cells, no clear correlation could be found. In
contrast, in a study conducted in mice a moderate correlation was
found between mRNA levels and presentation of corresponding
MHC class I peptides in normal versus neoplastic mouse
thymocytes [15]. Furthermore, the MHC class I peptide repertoire
was biased towards peptides derived from proteins encoded by high-
abundant mRNA transcripts in mouse thymocytes [15].
In the present study, we aimed at characterising both MHC class
I and II ligand-containing proteins with regard to their cellular
localisation and mRNA expression profile. This was achieved by
using the increased amount of experimentally-verifiedMHC ligands
in combination with the availability of functional annotations and
high throughput gene expression data of human proteins. Using a
large data set of proteins containing experimentally identified MHC
class I or II ligands obtained from the SYFPEITHI database [16],
we examined the proteins according to their Gene Ontology (GO)
classification within the cellular component ontology [17] and their
concentration at the mRNA level [18].
Results
Localisation of proteins containing MHC ligands
The SYFPEITHI database of MHC ligands and peptide motifs
[16] contains no externally imposed bias with respect to protein
cellular location, thus making it an ideal data set for investigating
the presence of biological bias in proteins containing MHC class I
or II ligands. For each MHC ligand in the SYFPEITHI database,
we retrieved a possible source protein. We then analysed
enrichment of GO terms in the cellular component ontology
among the proteins in our two data sets of proteins containing
MHC class I (MHCI data set) or MHC class II ligands (MHCII
data set) as compared to a background data set of all human
proteins with GO assignments. A graphical overview of the results
of the analysis is shown in Figure 1, while Table 1 shows a
selection of some of the most significantly enriched terms among
human proteins containing MHC class I or II ligands (note that
proteins can be assigned to more than one compartment resulting
in a total higher than 100%).
From Figure 1 it can be seen that the MHC class I ligand-
containing proteins are mainly enriched within terms in the centre
and right side of the figure. These include the terms ‘intracellular’,
‘organelle’, ‘cytoplasm’, and ‘nucleus’. As for the proteins containing
MHC class II ligands, the proteins are mainly enriched within terms
in the left side of Figure 1, including ‘membrane’, ‘plasma
membrane’, ‘extracellular region’, ‘vacuole’, and ‘lysosome’. The
MHC class II ligand-containing proteins are also slightly enriched
within the term ‘cytoplasm’ and some of its child nodes (‘cytoplasmic
part’, ‘cytosol’, and ‘cytosolic part’), although this enrichment is not
as significant as for the MHC class I ligand-containing proteins.
Table 1 shows that for some of the compartments enriched among
the proteins in the MHCII data set (‘membrane’ and ‘extracellular
region’), we observe lower fractions among the proteins in theMHCI
data set than in the entire human proteome as estimated from the
fractions of the background data set. On the other hand, for many
cellular compartments overrepresented among MHCI proteins
including ‘intracellular’, ‘organelle’, and ‘nucleus’, these are
underrepresented among proteins in the MHCII set.
Expression analysis - proteins containing MHC ligands
have elevated mRNA levels
Next, we analysed the expression profile of proteins containing
MHC class I or II ligands based on their mRNA abundance as
determined by DNA microarray analysis obtained from the GNF
gene expression database [18]. The data in the GNF expression
database were produced using Affymetrix whole genome chips
making them appropriate for this type of analysis. In the two
histograms in Figure 2, proteins with mRNA expression data are
ordered from left to right according to their mRNA level with
2.5% of the proteins in each bar. The height of the bars indicates
the fraction of proteins that contain MHC ligands at this level of
mRNA expression. Figure 2A shows that proteins encoded by
highly abundant mRNA more often contain MHC class I ligands
than proteins encoded by less abundant mRNA: In fact, 41% of
the proteins encoded by mRNA found in the top 2.5% highest
concentrations (the rightmost bar in Figure 2A) contain MHC
class I ligands. In contrast, only 3.2% of the proteins encoded by
mRNA found in the bottom 2.5% contain MHC class I ligands.
Overall, we find that mRNA encoding proteins that contain MHC
class I ligands are found in significantly higher concentrations than
that of mRNA encoding proteins with no known MHC class I
ligands (p,2.2*10216, Wilcoxon rank-sum test). For proteins
containing MHC class II ligands similar results are found:
Figure 2B demonstrates the existence of a clear correlation
between the level of mRNA and the occurrence of MHC class II
ligands in the encoded proteins with an extreme increase at the
right margin of the plot: For the 2.5% proteins encoded by the
most abundant mRNA, the probability that the proteins contain
an MHC class II ligand is 11%. Of the 2.5% proteins encoded by
the least abundant mRNA only 0.6% contain MHC class II
ligands. In general, proteins containing MHC class II ligands are
encoded by mRNA found in significantly higher concentrations
than that of proteins with no known MHC class II ligands
(p,2.2*10216, Wilcoxon rank-sum test).
Discussion
In the presented study, we have used large data sets of proteins
containing MHC class I or II ligands for investigating the source of
these important peptides. The proteins have been characterised as
regards to their cellular localisation as well as expression profile.
We have found that human proteins containing MHC class I
ligands are more frequently localised to intracellular parts of the cell
including the cytoplasm and nucleus than expected from the
distribution in a background protein data set. In a previous study
from 2004, the source of 200 B*1801-restrictedMHC class I ligands
were examined. It was likewise found that intracellular proteins are
the most overrepresented category in terms of MHC class I
presentation, although the authors state that ‘‘MHC class I peptides
can be derived from proteins resident to almost every compartment
in the cell and are not particularly biased toward the cytoplasmic
compartment’’ [8]. The difference in the final conclusion of the two
MHC Ligand-Containing Proteins
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Figure 1. Overview of GO cellular component terms enriched among proteins containing MHC ligands. The results from an enrichment
analysis were superimposed onto the GO tree structure; A: MHC class I ligand-containing proteins (MHCI data set) B: MHC class II ligand-containing
proteins (MHCII data set). Only nodes representing the most significant terms are included (p-value cut-offs used as inclusion criteria is 1.00*10213 for
the MHCI data set and 0.01 for the MHCII data set). The significance level is reflected by the node colour, where red corresponds to the most
significant p-values while grey indicates no enrichment. The size of the nodes reflects the number of proteins assigned to this term.
doi:10.1371/journal.pone.0007448.g001
MHC Ligand-Containing Proteins
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7448
studies, concerning whether or not there is a bias towards MHC
class I ligand-containing proteins being localised to the cytoplasm,
may be found in the size of the studies: The present study includes
more than five times as many MHC class I ligand-containing
proteins as the earlier study. Another difference between the two
studies is that the present study is not limited to proteins containing
MHC class I ligands restricted by a single MHC class I allele, but
includes all HLA-A and –B restricted ligands in the SYFPEITHI
database. In a recent study from 2008, a modest but significant
twofold enrichment in proteins located to the cytoplasm and nucleus
was found for proteins containing MHC class I ligands [15].
The main pathway leading to MHC class I presentation is
initiated when proteins are degraded by the proteasome. Yewdell
(2002) points out that: ‘‘A common misconception is that
proteasomes are located exclusively in the cytosol. In fact
proteasomes are present in the nucleus at similar or higher
concentration’’ [19]. In concordance with this observation, we find
that proteins located to both the cytoplasm and nucleus are
overrepresented as MHC class I ligand donors. Membrane
proteins are synthesised directly into the lumen of the ER [20],
which complicates their entry into the MHC class I pathway. The
fact that some membrane proteins do donate MHC class I ligands
is due to different mechanisms. By one mechanism, the MHC class
I ligands from membrane proteins originate from the signal
sequence that guides the nascent polypeptide chain to the ER. The
signal sequence is liberated from the rest of the protein by the
signal peptidase and may subsequently enter the lumen of the ER,
where further trimming can optimise it for binding to loadable
MHC class I molecules [6,21]. Proteins which fail to fold correctly
in the ER, may be transported back into the cytosol by reverse
translocation for degradation by the proteasome [22]. In this
study, we have only investigated the cellular localisation of human
proteins containing MHC class I ligands. Based on work on
poxvirus [23], Yewdell and Nicchitta (2006) suggest that ‘‘cell-
surface proteins, and even secreted proteins are equally efficient
and probable sources of antigenic peptides as cytosolic or nuclear
proteins’’ [9]. A study concerning an MHC class I ligand in the
HIV envelope (env) protein might shed light on the possible
difference between the localisation of human and viral proteins
containing MHC class I ligands [24]: The env protein is co-
translationally translocated into the ER during synthesis, but
nevertheless contains several different MHC class I ligands. One of
these ligands has the sequence TAVPWNASW. Although the
asparagine in the ligand is N-glycosylated inside ER, the authors
find that env-specific CTL clones only recognise the non-
glycosylated form. In addition, they find that the naturally
processed ligand is non-glycosylated. Since this specific ligand
has also been shown to be TAP-dependent [25], the results are
consistent with the hypothesis that the ligand is derived from
cytoplasmic env that have failed to engage the translocation
apparatus. It has been suggested that this failure is due to a
temporary excess of signal sequence-containing nascent polypep-
tides over signal recognition particles [6,24]. It may be a general
phenomenon during virus infection that the amount of signal
sequence-containing viral polypeptides present simultaneously
overloads the translocation apparatus. This would lead to cytosolic
localisation of viral membrane proteins, thus making them easily
accessible for the proteasome initiating the MHC class I pathway.
For human proteins containing MHC class II ligands, we see
opposite result as regards to localisation as compared to human
proteins containing MHC class I ligands: More MHC class II
ligand-containing proteins are localised to membranes. In
particular, plasma membrane proteins are overrepresented as
MHC class II donors. Several investigations have previously
reported that a large fraction of MHC class II ligands are derived
from host cell membrane proteins or host proteins resident in
Table 1. Fractions of MHC class I and II ligand-containing proteins that belong to a selection of GO cellular component terms.
Gene Ontology Term Fraction, MHCI Corrected P-value, MHCI Fraction, MHCII Corrected P-value, MHCII Fraction, background
cell 96.8% 2.05E-13 92.4% 0.443 91.1%
intracellular 86.7% 3.07E-60 61.6% 0.938 65.3%
organelle 69.3% 1.23E-33 49.2% 0.861 51.5%
cytoplasm 62.4% 8.88E-52 52.4% 4.42E-03 40.2%
nucleus 39.9% 3.57E-15 10.8% 1 28.8%
macromolecular complex 32.6% 2.94E-54 25.4% 8.58E-04 14.6%
cytosol 17.7% 3.88E-52 12.4% 1.42E-03 5.3%
organelle lumen 15.1% 1.04E-20 5.9% 0.861 7.0%
ribonucleoprotein complex 10.6% 7.69E-26 1.6% 0.995 3.6%
cytosolic ribosom 4.1% 3.93E-35 1.6% 0.125 0.4%
membrane 33.5% 1 58.9% 9.68E-05 42.8%
plasma membrane 14.5% 1 40.5% 1.81E-09 19.9%
extracellular region 5.6% 1 22.7% 2.27E-04 11.8%
integral to plasma membrane 4.5% 1 22.2% 1.04E-09 7.0%
vesicle 4.1% 0.023 14.1% 7.09E-10 2.8%
vacoule 1.5% 0.475 10.3% 6.25E-10 1.4%
lysosome 1.2% 0.705 9.2% 2.12E-09 1.2%
pigment granule 2.3% 1.65E-09 8.6% 1.27E-13 0.5%
melanosome 2.3% 1.65E-09 8.6% 1.27E-13 0.5%
Fractions and the corresponding p-values for some of the most significantly enriched terms are marked in bold. The p-values have been corrected for multiple testing
by the Benjamini & Hochberg correction method.
doi:10.1371/journal.pone.0007448.t001
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endosomes or lysosomes [7,10,11,26]. The primary function of
MHC class II presentation is thought to be activation of CD4+ T
cells on uptake and degradation of antigen from the extracellular
environment. Why then, are so many ligands derived from host
cell membrane proteins? Chicz et al. (1993) suggest that the self
peptides have a physiological role in modulating the immune
response [10]: Since overstimulation by antigen can induce
peripheral tolerance, the self ligands may serve not only to
prevent antigenic peptides with short binding half-lives from
binding, but also prevent over-presentation of foreign antigen in
vivo. Others have proposed what they call a ‘pseudodimer’ model
of T cell activation. In this model, heterodimers consisting of
MHC in complex with self-antigen and MHC in complex with
foreign peptide antigen, stabilised by CD4, are crucial interme-
diates for triggering CD4+ T lymphocytes [27] .
Regarding the expression profile of human MHC ligand-
containing proteins, we find a strong correlation between the
abundance of mRNA and the probability that the encoded protein
contains an MHC ligand. This is true for proteins containing both
MHC class I and II ligands, although the relationship is clearest
for proteins containing MHC class I ligands. In a study from 2008
conducted in mice, a similar result was found for MHC class I
ligands: Although only 9% of total mRNAs were expressed at high
levels, 42% of the mRNAs encoding MHC class I ligands were
expressed at high levels [15]. The results from the presents study
and the study from 2008 deal with MHC ligands in a purely
qualitative manner - does a particular protein contain an MHC
ligand or not? Quantitative comparisons of mRNA versus MHC
class I peptide levels have also been conducted. They have,
however, reached varying results. In a study from 2007, mRNA
levels were determined by DNA microarray analysis, while levels
of MHC class I in complex with peptides were determined by mass
spectrometry for 273 proteins and corresponding MHC class I
peptides in samples of renal cell carcinoma and their autologous
normal kidney tissue [14]. Next, the correlation between changes
in abundance in mRNA levels and changes in MHC class I
peptide levels in normal versus cancer cells were examined, but
found to be poor (r = 0.32). In another study, the correlation was
examined between changes in mRNA levels as determined by real-
time PCR and changes in MHC class I peptide levels as
determined by mass spectrometry in neoplastic versus normal
mouse thymocytes [15]. This analysis included only 47 mRNA
Figure 2. Distribution of MHC ligand-containing proteins relative to their mRNA expression level. The proteins were grouped into bins
of equal size, such that each bin contains 2.5% of all proteins in the data set. As a result, each bin comprises an equal number of proteins, increasing
in mRNA expression level from left to right. The height of each bar represents the fraction of proteins that contain MHC ligands. A: Fraction of
proteins that contain MHC class I ligands versus the mRNA expression level of the proteins according to the GNF gene expression database B:
Fraction of proteins that contain MHC class II ligands versus the mRNA expression level of the proteins according to the GNF gene expression
database.
doi:10.1371/journal.pone.0007448.g002
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and corresponding MHC class I peptide-pairs, but showed a
moderate correlation between relative mRNA levels and corre-
sponding MHC class I peptide levels (r = 0.63). The authors of the
latter study suggest that the stronger correlation in their case may
be caused by estimation of mRNA levels by real-time PCR rather
than microarrays [15]. Knowledge of the exact correlation
between mRNA levels and corresponding MHC class I peptide
levels may not be necessary for selecting proteins with relevance
for vaccine or diagnostic use as indicated by the following
observations: For CD4+ T lymphocytes, as little as about ten
MHC class II molecules with peptide cargo are sufficient for
activation [28], while for CD8+ T lymphocytes only three peptides
are needed for induction of cytotoxicity [29]. It may therefore
suffice to select proteins encoded by high-abundant mRNA, since
the present results show a 41% probability that proteins encoded
by the most high-abundant mRNA contain MHC class I ligands
and an 11% probability that they contain MHC class II ligands.
Our findings offer the possibility of extending the existing
methods for MHC ligand prediction by including the source
protein’s localisation and expression profile. Improving the current
methods is important in the growing quest for epitopes that can be
used for vaccine or diagnostic purposes, especially when it comes
to large DNA viruses and cancer.
Materials and Methods
Data set of proteins containing MHC ligands
InMay 2008, 2,164 peptides classified asMHC class I ligands and
860 peptides classified as MHC class II ligands were collected from
the SYFPEITHI database [16]. The corresponding source proteins
were retrieved from the UniProtKB database [30]. If more than one
human protein was the possible origin of a given peptide, the longest
one was chosen. 1,372 unique human source proteins were
identified for 2,062 MHC class I ligands (the MHCI data set, Data
set S1), while 246 unique human source proteins were identified for
699 MHC class II ligands (the MHCII data set, Data set S2).
Localisation enrichment analysis
The Gene Ontology (GO) project provides a controlled and
consistent vocabulary to describe the properties of proteins (gene
products) [17]. In order to test for overrepresentation of GO terms
among our two protein data sets, we applied a test in
hypergeometric distribution as implemented in the Cytoscape
plugin BINGO [31]. The p-values were corrected for multiple
testing by the Benjamini & Hochberg correction. The analysis was
performed separately for the cellular component ontology. For the
1,372 proteins in the MHCI data set, 1,109 had assignments in the
cellular component ontology. For the 246 proteins in the MHCII
data set, 185 had assignments in the cellular component ontology.
The entire human protein set was used as background, and for this
set 16,280 proteins with assignments to the cellular component
ontology were available. Table S1 lists the output from the
Cytoscape plugin BINGO analysis on the MHCI data set, while
Table S2 lists the output for the MHCII data set.
Expression analysis of proteins containing MHC ligands
The GNF gene expression database [18] contains mRNA
expression data on 79 distinct human tissues that have been
profiled in duplicates using the Affymetrix GeneChip Human
Genome U133A array. The data set has previously been shown to
display high reproducibility [32]. The data was normalised using
robust multi-array averaging (RMA) [33] and bias correction as
described in [34]. Among the tissue types in the GNF gene
expression database, we only used a subset: Since the ligand data
in the SYFPEITHI database has predominantly been obtained
from cells belonging to the haematopoietic lineage, our analysis
focuses on delineation of expression patterns in haematopoietic
tissues (BDCA4 Dendritic Cells, B Lymphoblasts, CD14 Mono-
cytes, CD19 B Cells, CD33 Myeloid Cells, CD34 Cells, CD4 T
Cells, CD56 NK Cells, CD71 Early Erythroid, CD8 T Cells,
Lymphoma Raji, Tonsil, WHOLEBLOOD(JJV), Bonemarrow,
Leukemia, Leukemia Lymphoblastic (molt4), Leukemia Promy-
elocytic (hl60), Lymph, Lymphnode, Lymphoma Burkitts Daudi,
and Thymus). The mRNA expression values for all tissues were
present in duplicates and for subsequent analysis the median
values for the tissues were calculated.
The MHC ligand-containing proteins in the MHCI and
MHCII data sets were integrated with data from the GNF gene
expression database [18]: We mapped the 22,283 probes on the
HG U133A array to UniProtKB accession numbers, which led to
12,489 unique proteins. If more than one probe mapped to a given
protein, the expression value of the mRNA encoding this protein
was taken as the median of the expression values for the individual
probes. Of the 12,489 unique proteins, 1,206 contained MHC
class I ligands and 200 contained MHC class II ligands (Table S3).
Wilcoxon rank-sum significance test for expression of
proteins containing MHC ligands
In order to assess if proteins containing MHC ligands are
significantly higher expressed than proteins not known to contain
MHC ligands, we used a non-parametric Wilcoxon rank-sum test.
We tested for equality of expression distribution between probes
mapping to proteins in the MHCI or MHCII data set as compared
to the remainder of the probes in the GNF gene expression database.
Supporting Information
Data set S1 The MHCI data set. The amino acid sequences of
the proteins in the MHCI data set in fasta format. The first
column of the headings lists the UniProtKB Accession number
and ID of the protein, the second column lists the starting position
of the MHC class I ligand in the protein, the third column lists the
amino acid sequence of the MHC class I ligand.
Found at: doi:10.1371/journal.pone.0007448.s001 (2.02 MB
DOC)
Data set S2 The MHCII data set. The amino acid sequences of
the proteins in the MHCII data set in fasta format. The first
column of the heading lists the UniProtKB Accession number and
ID of the protein, the second column lists the starting position of
the MHC class II ligand in the protein, the third column lists the
amino acid sequence of the MHC class II ligand.
Found at: doi:10.1371/journal.pone.0007448.s002 (0.56 MB
DOC)
Table S1 Localisation analysis of proteins containing MHC class
I ligands. The analysis was done using the Cytoscape plugin
BINGO on proteins in the MHCI data set. The entire human
protein set was used as background. GO-ID: The ID number of
the GO cellular component term. p-value: p-value indicating the
statistical significance of the difference between the fraction of
proteins containing MHC class I ligands assigned to this GO term
and the fraction of all proteins within the human protein set
assigned to this GO term. corr p-value: The above p-value
corrected for multiple testing by the Benjamini & Hochberg
correction method. x: The number of MHC class I-containing
proteins assigned to this GO term. nX: The number of proteins
within the entire human protein set assigned to this GO term. N:
The total number of MHC class I-containing proteins with
MHC Ligand-Containing Proteins
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assignments within the GO cellular component ontology. nN: The
total number of proteins within the human protein set with
assignments within the GO cellular component ontology.
Description: Description of the GO term.
Found at: doi:10.1371/journal.pone.0007448.s003 (0.20 MB
XLS)
Table S2 Localisation analysis of proteins containing MHC class
II ligands. The analysis was done using the Cytoscape plugin
BINGO on proteins in the MHCII data set. The entire human
protein set was used as background. GO-ID: The ID number of
the GO cellular component term. p-value: p-value indicating the
statistical significance of the difference between the fraction of
proteins containing MHC class II ligands assigned to this GO term
and the fraction of all proteins within the human protein set
assigned to this GO term. corr p-value: The above p-value
corrected for multiple testing by the Benjamini & Hochberg
correction method. x: The number of MHC class II-containing
proteins assigned to this GO term. nX: The number of proteins
within the entire human protein set assigned to this GO term. N:
The total number of MHC class II-containing proteins with
assignments within the GO cellular component ontology. nN: The
total number of proteins within the human protein set with
assignments within the GO cellular component ontology.
Description: Description of the GO term.
Found at: doi:10.1371/journal.pone.0007448.s004 (0.07 MB
XLS)
Table S3 mRNA expression levels of individual proteins.
mRNA expression levels are taken from the GNF gene expression
database. UniProtKB Acc: UniProtKB ACC number for the
protein. Affy ID: Affymetrix ID for probes mapping to the protein.
Expression value: Median expression value of all probes mapping
to the protein. MHCI: A ‘‘1’’ in this column indicates that this
protein is known to contain an MHC class I ligand, while ‘‘0’’
indicates that this protein is not known to contain an MHC class I
ligand. MHCII: A ‘‘1’’ in this column indicates that this protein is
known to contain an MHC class II ligand, while ‘‘0’’ indicates that
this protein is not known to contain an MHC class II ligand.
Found at: doi:10.1371/journal.pone.0007448.s005 (1.54 MB
XLS)
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